Revenue
2020
2021
2022
2023
Altamira Therapeutics Ltd. (CYTOF)
Price—Loading quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
Free cash flow
2015
2016
2017
2018
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
Financial statements
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | CHF379 | CHF305,616 | CHF63,882 | CHF174,475 | — | — | — | — | — |
| Gross profit | — | −CHF1.1M | −CHF2.2M | — | — | — | — | — | — |
| Research & development | CHF3.0M | CHF14.6M | CHF3.2M | CHF2.9M | CHF3.3M | CHF6.7M | CHF19.2M | CHF24.8M | CHF26.5M |
| Operating expenses | CHF29,321 | — | — | — | — | — | — | — | — |
| Operating income | −CHF5.9M | −CHF18.0M | −CHF6.9M | −CHF5.3M | −CHF7.3M | −CHF11.0M | −CHF24.4M | −CHF30.2M | −CHF30.9M |
| EBITDAderived | — | — | — | — | — | −CHF10.8M | −CHF24.3M | −CHF30.1M | — |
| Net income | −CHF3.9M | −CHF26.5M | −CHF17.1M | −CHF8.2M | −CHF6.6M | −CHF11.5M | −CHF24.4M | −CHF30.7M | −CHF29.7M |
| Basic EPSper diluted share | -CHF 7.88 | -CHF 582.58 | -CHF 515.11 | -CHF 25.27 | -CHF 2.28 | -CHF 14.46 | -CHF 111.61 | -CHF 8.93 | -CHF 0.92 |
| Diluted EPSper diluted share | -CHF 7.88 | -CHF 582.58 | -CHF 515.11 | -CHF 25.27 | -CHF 2.28 | -CHF 14.46 | -CHF 111.61 | -CHF 8.93 | -CHF 0.92 |